Sackler Colloquia banner

Life 2.0: The Promise and Challenge of a CRISPR Path to a Sustainable Planet

Organized by Barbara Meyer, Fyodor Urnov and Dana Carroll

Fully realizing the tremendous potential of gene editing will require such an interdisciplinary approach. The purpose of this colloquium is to enable a solution-oriented multidisciplinary dialog to address the following pressing questions: given the remarkable rate of progress in gene editing, what are the areas of its potential biggest impact on the planet in the next decade? what are the key obstacles – scientific, societal, economic – to that impact, in the Western world and in the developing world? The colloquium will thus gather leading experts, such as yourself, in various translational and societal aspects of gene editing (clinical; plant and animal agriculture); each session will conclude with a panel discussion aimed to identify, for a given real-world outcome, the key “pinch points” (scientific, economic, societal, political) on its path to the world.


  - A limited number of videos are available for public viewing.  More videos may be added as permission is received.


Tuesday, December 10, 2019

Welcome Remarks, Barbara Meyer, University of California, Berkeley

Keynote lecture, A View From the Edge, Dana Carroll, University of Utah and Innovative Genomics Institute

Session 1: The translational promise of CRISPR and the urgency of the challenge

Functional single-cell genomics of human cytomegalovirus infection, Jonathan Weissman, University of California, San Francisco

Taming the Wild through Genome Editing of Model and Non-Model Organisms, Barbara Meyer, University of California, Berkeley

How gene therapy can address the public health challenge of genetic disease, Michele Calos, Stanford University

Serving up Science: The Future of Food, Pamela Ronald, University of California, Davis

The return of global infections in an age of war, political collapse, antiscience, and climate change, Peter Hotez, Baylor College of Medicine

Session 2: Societal considerations and challenges

CRISPR and the meaning of solidarity in a Balkanized world, Debra Mathews, Johns Hopkins University School of Medicine

The voice of many: Collective oversight of environmental gene editing, Natalie Kofler, Yale University

Going from the clinic to the world, Dan Wattendorf, Gates Foundation

Connecting on CRISPR: Effective public communication about genome editing and its applications, Dietram Scheufele, Wisconsin University

Panel discussion: Fyodor Urnov, moderator

Session 3: Genome editing for animal engineering

Editing Farmed Animals, Bruce Whitelaw, Roslin Institute

Transform Xenotransplantation using CRISPR-Cas, Luhan Yang, Qihan Biotech

FDA’s Science- and Risk-Based Framework and Genome Editing in Animals, Heather Lombardi, U.S. Food and Drug Administration

Panel discussion: Dana Carroll, moderator

Distinctive Voices Lecture

Introduction by Barbara Meyer

Genome Editing with CRISPR-Cas systems: Challenges and Opportunities in a New Era of Biology, Jennifer Doudna, University of California, Berkeley

Wednesday, December 11, 2019

Session 4: Genome editing for crop engineering

Invigorating plant breeding with genome editing, Zach Lippman, Cold Spring Harbor Laboratory

Overcoming Bottlenecks in Plant Gene Editing, Daniel Voytas, University of Minnesota

USDA Approach to Regulating Plant Breeding Innovation, Neil Hoffman, USDA

Panel discussion: Barbara Meyer, moderator

Session 5: Gene drives

Exploiting CRISPR technology to develop population suppression gene drive solutions for vector borne diseases, Andrea Crisanti, Imperial College London

The next generation of gene drives, Bruce Hay, California Institute of Technology

Synthetic threads through the web of life, Mary Power, University of California, Berkeley

Panel discussion: Heather Lombardi, moderator

Session 6: Genome editing for disease

CRISPR Correction of Muscle Disease, Eric Olson, University of Texas Southwestern

The next generation of edited humans, Fyodor Urnov, Innovative Genomics Institute

The Regulatory Landscape for Genome Editing, Peter Marks, Food and Drug Administration Center for Biologics Evaluation and Research

Panel discussion: Dana Carroll, moderator

Session 7: Editing the human germline

Genome editing in human embryos, Kathy Niakan, Francis Crick Institute

Medical indications for future germline editing, Shruthi Mahalingaiah, Harvard University

Ethical and Social Issues in Human Germline Editing, John H. Evans, University of California, San Diego

Panel discussion: Fyodor Urnov, moderator

The National Academy of Sciences gratefully acknowledges the generous support for this colloquium from the following organizations:

Innovative Genomics Institute.


Powered by Blackbaud
nonprofit software